ArticleCell chemical biology2016
A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.
Article in Cell chemical biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 57 citations in OpenAlex.
- A Synthetic β-Mannan Epitope Enables Immunization and Detection of Candida auris.Angewandte Chemie (International ed. in English) · 2026Article
- Synthesis of Fluorinated Glycotope Mimetics Derived fromInternational journal of molecular sciences · 2025Article
- Synthetic BSA-conjugated disaccharide related to theFrontiers in immunology · 2024Article
- Strengths and weaknesses of pneumococcal conjugate vaccines.Glycoconjugate journal · 2023Review
- Synthetic Glycans to Improve Current Glycoconjugate Vaccines and Fight Antimicrobial Resistance.Chemical reviews · 2022Review
- Synthetic Glyconanoparticles Modulate Innate Immunity but Not the Complement System.ACS applied bio materials · 2022Article
- Synthesis of Oligosaccharides Resembling theOrganic letters · 2022Article
- Glycan Microarrays Containing Synthetic Streptococcus pneumoniae CPS Fragments and Their Application to Vaccine Development.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Semi- and fully synthetic carbohydrate vaccines against pathogenic bacteria: recent developments.Biochemical Society transactions · 2021Review
- Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance.Vaccines · 2021Review
- Discovery of Semi- and Fully-Synthetic Carbohydrate Vaccines Against Bacterial Infections Using a Medicinal Chemistry Approach.Chemical reviews · 2021Review
- Synthetic Analogs ofRussian journal of bioorganic chemistry · 2021Article
- Advances in the Chemical Synthesis of Carbohydrates and Glycoconjugates.Advances in biochemical engineering/biotechnology · 2021Review
- Chimeric oligosaccharide conjugate induces opsonic antibodies againstChemical science · 2020Article
- Higher Cytokine and Opsonizing Antibody Production Induced by Bovine Serum Albumin (BSA)-Conjugated Tetrasaccharide Related toFrontiers in immunology · 2020Article
- Various Tastes of Sugar: The Potential of Glycosylation in Targeting and Modulating Human Immunity via C-Type Lectin Receptors.Frontiers in immunology · 2020Review
- Synthesis ofBeilstein journal of organic chemistry · 2020Article
- Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens.Journal of visualized experiments : JoVE · 2019Article
- Microarray Strategies for Exploring Bacterial Surface Glycans and Their Interactions With Glycan-Binding Proteins.Frontiers in microbiology · 2019Review
- Improving vaccines againstProceedings of the National Academy of Sciences of the United States of America · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
Abstract
The identification of immunogenic glycotopes that render glycoconjugate vaccines protective is key to improving vaccine efficacy. Synthetic oligosaccharides are an attractive alternative to the heterogeneous preparations of purified polysaccharides that most marketed glycoconjugate vaccines are based on. To investigate the potency of semi-synthetic glycoconjugates, we chose the least-efficient serotype in the current pneumococcal conjugate vaccine Prevnar 13, Streptococcus pneumoniae serotype 3 (ST3). Glycan arrays containing synthetic ST3 repeating unit oligosaccharides were used to screen a human reference serum for antibodies and to define the recognition site of two ST3-specific protective monoclonal antibodies. The glycan array screens identified a tetrasaccharide that was selected for in-depth immunological evaluation. The tetrasaccharide-CRM197 carrier protein conjugate elicited protective immunity as evidenced by opsonophagocytosis assays and protection against pneumonia caused by ST3 in mice. Formulation of the defined protective lead candidate glycotope has to be further evaluated to elicit optimal long-term immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.